佐芬普利钙结构式
|
常用名 | 佐芬普利钙 | 英文名 | Zofenopril calcium |
---|---|---|---|---|
CAS号 | 81938-43-4 | 分子量 | 448.58 | |
密度 | 1.34 g/cm3 | 沸点 | 646.3ºC at 760 mmHg | |
分子式 | C22H22Ca0.5NO4S2 | 熔点 | >250ºC | |
MSDS | 中文版 美版 | 闪点 | 344.7ºC | |
符号 |
GHS09 |
信号词 | Warning |
佐芬普利钙用途Zofenopril Calcium(SQ26991)是抗氧化剂和血管紧张素转化酶(ACE)抑制剂。 |
中文名 | 佐芬普利钙 |
---|---|
英文名 | zofenopril calcium |
中文别名 | [(4S)-3-(苯甲酰硫基)-2(S)-甲基丙酰-4-(苯硫基)-L-脯氨酸]钙盐 |
英文别名 | 更多 |
描述 | Zofenopril Calcium(SQ26991)是抗氧化剂和血管紧张素转化酶(ACE)抑制剂。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.34 g/cm3 |
---|---|
沸点 | 646.3ºC at 760 mmHg |
熔点 | >250ºC |
分子式 | C22H22Ca0.5NO4S2 |
分子量 | 448.58 |
闪点 | 344.7ºC |
PSA | 228.56000 |
LogP | 7.80660 |
外观性状 | 白色或发白的结晶粉末 |
储存条件 | Refrigerator |
~% 佐芬普利钙 81938-43-4 |
文献:WO2007/3963 A1, ; Page/Page column 9; 11-12 ; |
~% 佐芬普利钙 81938-43-4 |
文献:US2009/176860 A1, ; Page/Page column 3 ; |
~% 佐芬普利钙 81938-43-4 |
文献:WO2010/84515 A2, ; Page/Page column 34 ; |
~% 佐芬普利钙 81938-43-4 |
文献:WO2010/84515 A2, ; Page/Page column 33-34 ; |
佐芬普利钙上游产品 3 | |
---|---|
佐芬普利钙下游产品 0 |
Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions.
Cardiovasc. Ther. 27(4) , 275-88, (2009) Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infa... |
|
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of zofenopril and its active metabolite zofenoprilat in human plasma.
J. Pharm. Biomed. Anal. 55(3) , 527-32, (2011) A novel, sensitive and rapid liquid chromatographic-electrospray ionization mass spectrometric method was developed and validated for the determination of zofenopril and its active metabolite zofenopr... |
|
Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits.
J. Cardiovasc. Pharmacol. Ther. 15(4) , 384-92, (2010) Cough is the most common symptom reported by patients in a primary care setting and is one of the most frequent secondary effects recorded during treatment with angiotensin-converting enzyme (ACE) inh... |
Calcium bis[(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)-2-pyrrolidinecarboxylate] |
ZOFENOPRIL CALCIUM |
Calcium bis[(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylate] |
L-Proline, 1-[(2S)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, calcium salt, (4S)- (2:1) |
MFCD08704648 |
Zofenopril calcium salt |